<SEC-DOCUMENT>0001104659-25-080754.txt : 20250922
<SEC-HEADER>0001104659-25-080754.hdr.sgml : 20250922
<ACCEPTANCE-DATETIME>20250820121743
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-25-080754
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250820

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;<IMG SRC="image_001.jpg" ALT="Protalix BioTherapeutics Announces Presentations at the 17th ..." STYLE="height: 101px; width: 192px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">August
20, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><U>Via
EDGAR</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">Securities
and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">Division
of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">Office
of Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">100
F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">Washington,
D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.05pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; width: 0.5in; text-indent: 0">Re:</TD>
    <TD STYLE="padding: 0; text-indent: 0"><B>Protalix BioTherapeutics, Inc.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 0; text-indent: 0"><B>Registration Statement on Form S-3</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 0; text-indent: 0"><B>File No. 333-286802</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To whom it may concern:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31pt">Pursuant to Rule
461 under the Securities Act of 1933, as amended, Protalix BioTherapeutics, Inc. (the &ldquo;<U>Company</U>&rdquo;) hereby respectfully
requests that the effective date of the above-referenced Registration Statement on Form S-3 be accelerated by the Securities and Exchange
Commission to 4:00 p.m. Eastern Time on August 22, 2025, or as soon as practicable thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company requests
that we be notified of such effectiveness by a telephone call to Brian Hirshberg of Mayer Brown LLP at +1 (212) 506-2176.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0; text-indent: 0">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; width: 50%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; width: 3%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; width: 6%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; width: 41%; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><B>&nbsp;</B></TD>
    <TD COLSPAN="3" STYLE="padding: 0; text-indent: 0"><B>Protalix BioTherapeutics, Inc. </B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding: 0; text-indent: 0">/s/ Eyal Rubin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Name:</TD>
    <TD STYLE="padding: 0; text-indent: 0">Eyal Rubin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Title:&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Sr. Vice President and Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; width: 0.5in; text-align: justify; text-indent: 0">cc:</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Dror Bashan </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Protalix BioTherapeutics, Inc.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Brian Hirshberg</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Mayer Brown LLP</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 227pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 227pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 227pt 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !E , # 2(  A$! Q$!_\0
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MES86ESJ6I@_VAJ+^;(#U0=0#[\D_E0!2^(_^LT#_ *_U_I7;UQ'Q'_UF@?\
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I%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
